Somatic IDH1 Hotspot Variants in Chinese Patients With Pheochromocytomas and Paragangliomas

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Minghao Li - , Central South University (Author)
  • Yao He - , China Medical University (Author)
  • Yingxian Pang - , Central South University (Author)
  • Jing Zhang - , Fudan University (Author)
  • Yu Feng - , Soochow University (Author)
  • Yao He - , Central South University (Author)
  • Xiaowen Xu - , Central South University (Author)
  • Yongbao Wei - , Fujian Medical University (Author)
  • Dewen Zhong - , Fujian Medical University (Author)
  • Wanglong Deng - , The First People’s Hospital of Chenzhou (Author)
  • Long Wang - , Central South University (Author)
  • Bin Yan - , Central South University (Author)
  • Yazhuo Jiang - , Xi'an Jiaotong University (Author)
  • Ning Xu - , Fujian Medical University (Author)
  • Hai Cai - , Fujian Medical University (Author)
  • Yanlin Wen - , North Sichuan Medical College (Author)
  • Jinzhuo Ning - , Wuhan University (Author)
  • Yujun Liu - , Fudan University (Author)
  • Xin Gao - , Fudan University (Author)
  • Zhongyan Shan - , China Medical University (Author)
  • Longfei Liu - , Central South University (Author)
  • Xiaochun Teng - , China Medical University (Author)
  • Susan Richter - , Institute of Clinical Chemistry and Laboratory Medicine (Author)
  • Jingjing Jiang - , Fudan University (Author)

Abstract

Context: IDH1 is a pheochromocytoma/paraganglioma (PPGL) susceptibility gene; however, its role, especially in the Chinese population, has not been characterized. Objective: To determine the prevalence of somatic IDH1 hotspot variants in a large cohort of Chinese patients with PPGLs and to summarize associated phenotypes. Methods: This retrospective cross-sectional study was based on a main cohort of 1141 patients with PPGLs from 2 tertiary-care centers in China. We included 50 cases with urinary bladder paragangliomas (UBPGLs), of whom 29 were part of the main cohort and 21 were from other centers. Two additional cases with IDH1 hotspot variants not part of the main cohort were also included for summarizing IDH1associated phenotypes. Next-generation sequencing of tumor DNA was used to analyze a customized panel of genes. Results: The overall prevalence of IDH1 hotspot variants in the main cohort was 0.5% (6/1141). Among those PPGLs without mutations in 15 common driver genes, the prevalence of IDH1 variants was 0.9% (4/455). When restricted to paraganglioma (PGL) without mutations, the prevalence reached 4.7% (4/86). Among UBPGLs, IDH1 hotspot variants accounted for 8% (4/50). Together, all 10 patients (9 PGLs and 1 pheochromocytoma) with IDH1 hotspot variants, including 3 females with concurrent EPAS1 hotspot variants, had apparently sporadic tumors, without metastasis or recurrence. There were 3 patients with biochemical data, all showing a non-adrenergic phenotype. Conclusions: The somatic IDH1 hotspot variants cause PPGL development in some Chinese patients, especially among those apparently sporadic PGLs with a non-adrenergic phenotype and without mutations in major PPGL driver genes.

Details

Original languageEnglish
Pages (from-to)1215-1223
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume108
Issue number5
Publication statusPublished - 13 Apr 2023
Peer-reviewedYes

External IDs

PubMed 36355572
ORCID /0000-0002-3549-2477/work/142244907
WOS 000891554700001

Keywords

Research priority areas of TU Dresden

Sustainable Development Goals

Keywords

  • IDH1, paraganglioma, pheochromocytoma, Adrenal Gland Neoplasms/epidemiology, Cross-Sectional Studies, Paraganglioma/epidemiology, Humans, Female, Retrospective Studies, Isocitrate Dehydrogenase/genetics, East Asian People, Pheochromocytoma/epidemiology